Table 1.
Baseline characteristics: For categorical variables, count (percent) are presented, for scalar variables median [interquartile range] is presented. p < 0.05 was considered statistically significant.
| Data Available N (%) |
All Patients N = 337 (100%) | 1-Month VT Recurrence | 1-Year VT Recurrence | |||||
|---|---|---|---|---|---|---|---|---|
| 1-Month VT Recurrence N = 60 (18%) |
No 1-Month VT Recurrence N = 277 (82%) |
p | 1-Year VT Recurrence N = 117 (35%) |
No 1-Year VT Recurrence N = 220 (65%) |
p | |||
| Age | 337 (100%) | 68.7 (60.2–74.8) | 68.2 (61.6–76.1) | 68.7 (60.1–74.8) | 0.619 | 67.5 (61.1–74.7) | 68.9 (59.3–75.0) | 0.934 |
| Male | 337 (100%) | 295 (88%) | 51 (85%) | 244 (88%) | 0.659 | 102 (87%) | 192 (88%) | 1.000 |
| Atrial fibrillation | 337 (100%) | 109 (32%) | 25 (42%) | 84 (30%) | 0.126 | 45 (38%) | 64 (29%) | 0.109 |
| Hypertension | 337 (100%) | 252 (75%) | 43 (72%) | 209 (76%) | 0.622 | 83 (71%) | 169 (77%) | 0.261 |
| Diabetes | 337 (100%) | 113 (34%) | 18 (30%) | 95 (34%) | 0.613 | 43 (37%) | 70 (32%) | 0.445 |
| COPD | 337 (100%) | 42 (12%) | 8 (13%) | 34 (12%) | 1.000 | 13 (11%) | 29 (13%) | 0.697 |
| CAD | 337 (100%) | 283 (84%) | 48 (80%) | 235 (85%) | 0.426 | 95 (81%) | 188 (86%) | 0.339 |
| ICD | 337 (100%) | 249 (74%) | 47 (78%) | 202 (73%) | 0.508 | 95 (81%) | 154 (70%) | 0.042 * |
| CRT | 337 (100%) | 80 (24%) | 20 (33%) | 60 (22%) | 0.081 | 42 (36%) | 38 (17%) | <0.001 * |
| HF | 331 (98%) | 272 (82%) | 53 (88%) | 219 (81%) | 0.234 | 100 (85%) | 172 (80%) | 0.314 |
| NYHA | 306 (91%) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.120 | 2 (1–3) | 2 (1–3) | 0.027* |
| SCD | 337 (100%) | 61 (18%) | 12 (20%) | 49 (18%) | 0.823 | 19 (16%) | 42 (19%) | 0.605 |
| EF | 305 (91%) | 34 (27–42) | 30 (25–35) | 35 (27.2–43) | 0.012 * | 33 (25–38) | 35 (28–44.2) | 0.008 * |
| LVESD | 283 (84%) | 50 (42–57) | 54 (47–60) | 48.5 (41–56) | 0.011 * | 53 (47–59) | 47 (41–54) | <0.001 * |
| TAPSE | 264 (78%) | 19 (15–23) | 17 (14–20) | 19 (16–23) | 0.019 * | 18 (14–20.2) | 19 (16–23) | 0.028 * |
| E wave DT | 262 (78%) | 162 (133–213) | 150 (123–193) | 165 (137–220) | 0.083 | 150 (127–200) | 170 (140–220) | 0.008 * |
| MR | 299 (89%) | 2 (1–2) | 2 (1–3) | 2 (1–2) | 0.036 * | 2 (1–3) | 2 (1–2) | 0.007 * |
| TR III-IV | 278 (82%) | 34 (12%) | 8 (15%) | 26 (12%) | 0.592 | 13 (13%) | 21 (12%) | 0.881 |
| Amiodarone | 331 (98%) | 233 (70%) | 47 (80%) | 186 (68%) | 0.118 | 88 (76%) | 145 (67%) | 0.140 |
| Beta blocker | 331 (98%) | 302 (91%) | 53 (90%) | 249 (92%) | 0.867 | 106 (91%) | 196 (91%) | 1.000 |
| ICD shock | 333 (99%) | 140 (42%) | 33 (57%) | 107 (39%) | 0.018 * | 60 (52%) | 80 (37%) | 0.009 * |
| HD instability | 337 (100%) | 132 (39%) | 36 (60%) | 96 (35%) | 0.001 * | 58 (50%) | 74 (34%) | 0.007 * |
| Incessant VT | 337 (100%) | 114 (34%) | 30 (50%) | 84 (30%) | 0.006 * | 52 (44%) | 62 (28%) | 0.004 * |
| Electrical storm | 336 (100%) | 135 (40%) | 35 (58%) | 100 (36%) | 0.003 * | 57 (49%) | 78 (36%) | 0.027 * |
| Inducible VT morphologies | 334 (99%) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 0.166 | 1 (1–2) | 1 (1–2) | 0.001 * |
| Clinical VT inducible | 333 (99%) | 261 (78%) | 49 (83%) | 212 (77%) | 0.431 | 104 (90%) | 157 (72%) | <0.001 * |
| Non-clinical VT(s) inducible | 332 (99%) | 106 (32%) | 21 (36%) | 85 (31%) | 0.609 | 38 (33%) | 68 (31%) | 0.909 |
| Clinical VT cycle length | 268 (80%) | 400 (340–460) | 400 (342–450) | 400 (340–460) | 0.828 | 400 (354–458) | 386 (333–458) | 0.114 |
| Clinical VT eliminated | 321 (95%) | 284 (88%) | 44 (79%) | 240 (91%) | 0.020 * | 100 (88%) | 184 (88%) | 1.000 |
| All VTs eliminated | 322 (96%) | 255 (79%) | 40 (70%) | 215 (81%) | 0.095 | 91 (80%) | 164 (79%) | 0.950 |
| Major complications | 334 (99%) | 32 (10%) | 10 (17%) | 22 (8%) | 0.061 | 15 (13%) | 17 (8%) | 0.186 |
COPD: chronic obstructive pulmonary disease; SCD: sudden cardiac death; CAD: coronary artery disease; ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; HF: heart failure; NYHA: New York Heart Association functional status; LVEF: left ventricular ejection fraction; LVESD: left ventricular end systolic diameter; TAPSE: tricuspid annular plane excursion; MR: mitral regurgitation; HD: hemodynamic. The asterix (*) denotes statistical significance.